Sugi Predict

Sugi Predict / Compounds / SCHEMBL514964

SCHEMBL514964

SCHEMBL514964

C[C@](N)(C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.51
▸ CYP2D6 P10635 3/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ PTPN1 P18031 1/20 0.46
▸ KIF11 P52732 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ CASR P41180 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ EPHX1 P07099 1/20 0.39
▸ KAT6A Q92794 1/20 0.39
▸ PTPN7 P35236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755686 1.00 CYP1A2 (0.51) CYP1A2CYP2D6CYP2C19PTPN1KIF11
SCHEMBL5970098 1.00 CYP1A2 (0.51) CYP1A2CYP2D6CYP2C19PTPN1KIF11
SCHEMBL17545257 0.85 CYP1A2 (0.48) CYP1A2CYP2D6CYP2C19PKMCYP3A4
SCHEMBL17681750 0.83 KIF11 (0.42) CYP1A2CYP2D6CYP2C19PTPN1KIF11
SCHEMBL9043333 0.82 PPARA (0.54) PKMPPARAMAPTPTPN7
SCHEMBL9719820 0.81 PTPN1 (0.49) CYP2D6PTPN1KIF11CASRCYP3A4
SCHEMBL4678770 0.81 PTPN1 (0.49) CYP2D6PTPN1KIF11CASRCYP3A4
SCHEMBL11884018 0.81 KDM4E (0.51) CYP1A2CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL21296669 0.80 KCNN4 (0.42) CYP1A2PTPN1KIF11CASRSLC6A2
SCHEMBL7861321 0.80 PTPN1 (0.47) CYP2D6PTPN1KIF11CASRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719486-A1 CONJUGATES AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 — — EP claimed
WO-2024245407-A1 CONJUGATES AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-12-05 — — WO claimed
US-20120027706-A1 METHODS FOR TREATING SKIN PIGMENTATION SHAPIRO STANLEY S (US) 2012-02-02 — — US claimed
JP-4401441-B2 — — 2010-01-20 — — JP claimed
US-20080249029-A1 Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator SHAPIRO STANLEY S 2008-10-09 — — US claimed
EP-1419178-B1 SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE UNIV BERN (CH) 2006-05-31 — — EP claimed
EP-1194425-B1 SUBSTITUTED BENZIMIDAZOLE AVENTIS PHARMA GMBH (DE) 2005-08-10 — — EP claimed
EP-1419178-A1 SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE University of Bern (CH) 2004-05-19 — — EP claimed
WO-2003014158-A1 SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE UNIVERSITY OF BERN (CH) 2003-02-20 — — WO claimed
EP-1283216-A1 Somatostatin analogues binding to all somatostatin receptor subtypes and their use Mallinckrodt Inc. (US) 2003-02-12 — — EP claimed
JP-2001502360-A — — 2001-02-20 — — JP claimed
CN-1234735-A Method for treating skin pigmentation JOHNSON & JOHNSON CONSUMER (US) 1999-11-10 — — CN claimed
EP-0948308-A1 METHODS FOR TREATING SKIN PIGMENTATION JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) 1999-10-13 — — EP claimed
WO-1999004752-A9 METHODS FOR TREATING SKIN PIGMENTATION JOHNSON & JOHNSON CONSUMER (US) 1999-04-08 — — WO claimed
WO-1999004752-A2 METHODS FOR TREATING SKIN PIGMENTATION JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 1999-02-04 — — WO claimed
EP-0833839-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1998-04-08 — — EP claimed
WO-1996040741-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 — — WO claimed
WO-1996040742-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 — — WO claimed
WO-1996040748-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 — — WO claimed
US-5523308-A SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES ORTHO PHARMACEUTICAL CORPORATION 1996-06-04 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027706-A1 METHODS FOR TREATING SKIN PIGMENTATION TYR, MC1R, NQO1 CYP1A2 270/4885CYP2D6 2383/4885CYP2C19 2040/4885
US-20080249029-A1 Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator MC1R, F2RL1, F2R CYP1A2 749/4885CYP2D6 2191/4885CYP2C19 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.